

## Quick Reference Coding Guide

### Healthcare Provider Office Setting

	Coding system	Example codes*
<b>Diagnosis codes</b>	ICD-9-CM	555.0 Regional enteritis small intestine 555.1 Regional enteritis large intestine 555.2 Regional enteritis small intestine with large intestine 555.9 Regional enteritis unspecified site 714.0 Rheumatoid arthritis 714.2 Other rheumatoid arthritis with visceral or systemic involvement
<b>Drug/biologic codes</b>	HCPCS	J0718 Certolizumab pegol, 1 mg
	NDC	<b>50474-710-79 (2 x 200-mg) prefilled syringes</b> 50474-700-62 (2 x 200-mg) lyophilized powder vials
<b>Drug administration codes</b>	CPT <sup>®</sup>	96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular [OR] 96401 Chemotherapy administration; subcutaneous or intramuscular (Medicare, Medicaid, or private payor)

### Hospital Outpatient Setting

	Coding system	Example codes*
<b>Diagnosis codes</b>	ICD-9-CM	555.0 Regional enteritis small intestine 555.1 Regional enteritis large intestine 555.2 Regional enteritis small intestine with large intestine 555.9 Regional enteritis unspecified site 714.0 Rheumatoid arthritis 714.2 Other rheumatoid arthritis with visceral or systemic involvement
<b>Drug/biologic codes</b>	HCPCS	J0718 Certolizumab pegol, 1 mg
	NDC	<b>50474-710-79 (2 x 200-mg) prefilled syringes</b> 50474-700-62 (2 x 200-mg) lyophilized powder vials
<b>Drug administration codes</b>	CPT <sup>®</sup>	96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular [OR] 96401 Chemotherapy administration; subcutaneous or intramuscular (Medicare, Medicaid, or private payor)

**\*Note:** Healthcare providers should select the most appropriate codes with the highest level of detail to describe the patient's condition and the services rendered to the patient. It is the healthcare provider's sole responsibility to determine and submit appropriate codes. Commercial payors may continue to use codes that have been discontinued for use in Medicare claims processing. Healthcare providers should contact insurers to verify coverage and correct coding procedures prior to submitting claims, as information on coverage and coding is subject to change without notice.

The rate of adoption for some Medicaid programs and private payors may vary with the new J-code, J0718. The CIMplicity™ Service Center can assist in verifying acceptance of J0718 by specific payors to ensure that payor claims systems have been updated to accept this new J-code. UCB encourages that providers use the CIMplicity Service Center and/or contact third-party payors for specific information on their coding, coverage, and payment policies.

CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis.

**Serious and sometimes fatal side effects have been reported with CIMZIA. These include tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.**

Please ask Sales Representative for full Prescribing Information or visit [www.cimzia.com](http://www.cimzia.com).

For more information, contact the **cimplicity** service center:

Hours 8:00 AM to 8:00 PM, EST, Monday through Friday Fax 1-866-949-2469

Phone 1-866-4-CIMZIA (1-866-424-6942) Web site [www.cimzia.com](http://www.cimzia.com)